Collegium inflammation news
Collegium will sell or out-license its respiratory portfolio and refocus on its DETERx abuse deterrent technology, COL-003 and marketing its skin and skin care product portfolio. Collegium's respiratory portfolio includes AllerNase triamcinolone acetonide, an aqueous based intranasal steroid to treat seasonal and perennial allergic rhinitis; COL-131, a sustained-release liquid formulation of an undisclosed compound to treat cough and cold symptoms; and two OTC products. AllerNase is under FDA review with an Aug. 4 PDUFA date. COL-131 is expected to start Phase I testing this half. AllerNase is a reformulation of Tri-Nasal triamcinolone acetonide nasal spray, which Collegium acquired in 2003 from Muro Pharmaceuticals Inc. (see BioCentury, Oct. 12, 2003). ...